P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERAT...

por Hanna, M., Chorazy, J., Iheanacho, I., Gorsh, B., Wang, P.F., Paka, P., Perera, S.
Publicado 2023

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY

por Roussel, M., Texier, N., Germain, R., Sapra, S., Paka, P., Kerbouche, N., Colin, X., Leleu, X.
Publicado 2023

P943: SURVIVAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA IN FRANCE: A COHORT STUDY USING THE FRENCH NATIONAL HEALTHCARE DATABASE (SNDS)

por Leleu, X., Gorsh, B., Bessou, A., Paka, P., De Nascimento, J., Colin, X., Landi, S., Wang, P. F.
Publicado 2022